STOCK TITAN

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotech focused on IL-1β pathway therapeutics for immune-mediated inflammatory diseases, will participate in the Leerink Partners Therapeutics Forum.

Management plans to host one-on-one investor meetings on July 15, 2026, in Boston.

Loading...
Loading translation...
Argus Jul 7 session 2 alerts
-3.56% close to close 0.7x rel. volume Open Argus
Details

Market move: AVTX -3.56% in the Jul 7 session. conference participation

$1.05B Mkt Cap at Peak Alert

On Jul 7, the day this news came out, AVTX closed 3.56% below the previous close. Our momentum scanner recorded 2 alerts in the available session data.

Data tracked by StockTitan Argus for the Jul 7 session.

Key Figures

Conference date: July 15, 2026
Conference date
July 15, 2026
Leerink Partners Therapeutics Forum in Boston

Historical Context

5 past events · Latest: Jun 26
5 events
  1. Jun 26

    Index inclusion news

    24h Move
    +1.1%

    Added to Russell 2000 and 3000 indexes, boosting index investor exposure.

  2. Jun 23

    Board appointment

    24h Move
    +4.4%

    Added experienced biopharma executive to board following positive trial data.

  3. Jun 16

    Pipeline expansion

    24h Move
    -1.9%

    Advanced AVTX-010 next-generation anti-IL-1β antibody toward IND filing.

  4. May 22

    Inducement option grant

    24h Move
    -2.0%

    Granted stock option inducement award to new employee under Nasdaq rule.

  5. May 13

    Q1 results update

    24h Move
    -0.5%

    Reported Q1 2026 loss alongside financing and positive Phase 2 LOTUS data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is an anti-IL-1β monoclonal antibody (mAb). Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa (HS). In addition to HS, we’re exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. We are also advancing AVTX-010, a long-acting next-generation anti-IL-1β mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart. For more information about Avalo, please visit www.avalotx.com.

For media and investor inquiries

Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Avalo Therapeutics (AVTX) attend the Leerink Partners Therapeutics Forum in 2026?

Avalo Therapeutics will participate in the Leerink Partners Therapeutics Forum on July 15, 2026. According to Avalo Therapeutics, management will host one-on-one investor meetings during the event in Boston to engage with current and potential shareholders.

What is Avalo Therapeutics (AVTX) planning to do at the 2026 Leerink Partners Therapeutics Forum?

Avalo Therapeutics plans to host one-on-one investor meetings at the 2026 Leerink Partners Therapeutics Forum. According to Avalo Therapeutics, these meetings will allow management to discuss the company’s IL-1β pathway-focused pipeline and strategy with institutional investors in Boston.

Where will Avalo Therapeutics (AVTX) hold investor meetings during the July 15, 2026 forum?

Avalo Therapeutics will hold investor meetings in Boston during the July 15, 2026 Leerink Partners Therapeutics Forum. According to Avalo Therapeutics, management will conduct one-on-one sessions with investors to provide corporate and pipeline updates on its immune-mediated inflammatory disease programs.

What type of company is Avalo Therapeutics (AVTX) participating in the 2026 Leerink forum?

Avalo Therapeutics is a clinical-stage biotechnology company focused on IL-1β pathway therapeutics. According to Avalo Therapeutics, the company is fully dedicated to developing treatments for immune-mediated inflammatory diseases and will discuss this strategy during investor meetings at the Leerink Partners Therapeutics Forum.

Why might Avalo Therapeutics (AVTX) investor meetings at the Leerink forum matter to shareholders?

The investor meetings may help increase awareness of Avalo Therapeutics’ strategy and pipeline among institutional investors. According to Avalo Therapeutics, hosting one-on-one meetings in Boston offers a platform to communicate its IL-1β pathway focus and clinical-stage programs to the investment community.

Keep reading